# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benny Leonard (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX008-SYN
- Date: 2026-08-25
- Fictional facility: St. Posthumous Health Center
- Fictional author: Miriam Okafor-Rosenthal, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Fifteen-week review: blood pressure on the new medicines, kidney function and the sick visit. **S**

## History of present illness

Mr. Leonard returns four weeks after the preventive visit, when losartan-hydrochlorothiazide was replaced by losartan 100 mg and amlodipine 5 mg after an episode of volume depletion in the July heat. He has had no lightheadedness since, and he drinks water between bouts and carries the sick-day card. He has refereed full cards every week without chest tightness or breathlessness, including two hot nights. His home readings over the past week averaged 122/76 mmHg. He has slight ankle puffiness at the end of a fight night that is gone by morning. His HIV and hepatitis C tests were negative and the hepatitis B panel showed no immunity; his stool test for colon cancer was negative. He says the money worry is less now that he is working steadily. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 122/76 mmHg over seven days |
| Kidney function | Creatinine 1.02 mg/dL, potassium 4.4 mmol/L, four weeks after the change |
| Screening | HIV and hepatitis C negative; hepatitis B not immune; FIT negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Slight ankle puffiness at the end of fight nights; no chest tightness, palpitations or fainting |
| Constitutional | Negative | No lightheadedness or tiredness |
| Respiratory | Negative | No breathlessness at work |

3 systems reviewed. **S**

## Current medications

- Atorvastatin 40 mg tablet, one each evening **S**
- Losartan 100 mg tablet, one each morning **S**
- Amlodipine 5 mg tablet, one each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 73.4 kg; BMI 27 kg/m². All vital signs are synthetic.

Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Urea nitrogen: 15 mg/dL; Creatinine: 1.02 mg/dL; eGFR: 88 mL/min/1.73 m²; Glucose: 93 mg/dL. All results are synthetic.

## Change since baseline

- Sodium: 140 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Urea nitrogen: 15 mg/dL at baseline, 15 mg/dL at this visit **S**
- Creatinine: 0.98 mg/dL at baseline, 1.02 mg/dL at this visit **S**
- eGFR: 93 mL/min/1.73 m² at baseline, 88 mL/min/1.73 m² at this visit **S**
- Glucose: 96 mg/dL at baseline, 93 mg/dL at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 1 of 2, after a screening panel showed no immunity **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/78 mmHg, pulse 68; weight 73.4 kg; no orthostatic fall |
| Cardiovascular | Regular rhythm; fourth heart sound softer; no murmur; trace ankle edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertensive heart disease** (I11.9). At goal: clinic 124/78 mmHg and home 122/76 mmHg on losartan 100 mg and amlodipine 5 mg, with normal kidney function and potassium. Trace ankle edema from amlodipine does not trouble him. **S**
   - Continue losartan 100 mg and amlodipine 5 mg.
   - Basic metabolic panel every six months.
   - Repeat echocardiogram six to twelve months after the first.
2. **Coronary atherosclerosis (calcium score 186)** (I25.10). LDL 66 mg/dL at the preventive visit, at goal on atorvastatin 40 mg; no exertional symptoms. **S**
   - Continue atorvastatin; lipid panel in a year.
   - Aspirin to be discussed at the next visit now that blood pressure is controlled.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Clinic blood pressure, average of two seated readings | Every visit | Completed today | 124/78 mmHg |
| Self-management | Home blood pressure monitoring (validated upper-arm cuff), readings sent weekly | Every day during titration; then a week before each visit | Completed today | Seven-day average 122/76 mmHg: at goal |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR) | Two to four weeks after starting or changing an ARB or diuretic; then every six months | Deferred | The panel ordered two weeks after the dose increase at the seven-week visit was not drawn: he was refereeing four nights that week, and no reminder call was made. The next check was at the sick visit three weeks after the increase, during volume depletion in a heat wave (creatinine 1.44 mg/dL, potassium 3.3 mmol/L), which recovered within a week. An earlier check would probably have been normal and would not have prevented the heat-related episode, but a fall in potassium on the higher thiazide dose could have been found sooner. Corrective action: a standing laboratory order with a reminder call for every check after a medication change |
| Laboratory | Basic metabolic panel (sodium, potassium, creatinine, eGFR), after the change to losartan and amlodipine | Two to four weeks after a change | Completed today | Sodium 140, potassium 4.4 mmol/L, creatinine 1.02 mg/dL, eGFR 88 |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | LDL 66 mg/dL at nine weeks (preventive visit); next in a year |
| Examination | Fundoscopic examination | Yearly | Up to date | Mild arteriolar narrowing at the preventive visit |
| Examination | Symptoms: exertional chest discomfort, breathlessness, palpitations, fainting | Every visit | Completed today | None at full cards, including hot nights |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension or suspected hypertrophy; repeat in six to twelve months to judge regression | Up to date | Repeat due six to twelve months after the first |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 73.4 kg, BMI 27.0 |
| Medication safety | Adherence and side effects (cough, edema, muscle aches, lightheadedness) | Every visit | Completed today | Trace ankle edema on amlodipine; no lightheadedness or muscle aches |
| Self-management | Sick-day rules | When starting an ARB or diuretic | Completed today | Carries the wallet card; knows to skip losartan on sick or very hot days without drinking |
| Self-management | Return to work: refereeing, heat and hydration, warning symptoms, defibrillator at the venue | Before return to full exertion; then every visit | Completed today | Full cards weekly with water between bouts; the venue has a defibrillator at ringside |

## Goal progress

- Find the cause of the exertional breathlessness and chest tightness. Outcome by 2026-05-26: No inducible ischemia; symptoms from hypertensive heart disease with an exaggerated blood pressure response. **S**
- Blood pressure below 130/80 mmHg at home and in the clinic. Outcome by 2026-08-25: 164/100 at intake to 124/78 in the clinic, home average 122/76 mmHg. **S**
- LDL below 70 mg/dL and at least 50% lower than at intake. Outcome by 2026-07-28: LDL 160 to 66 mg/dL (59% lower) on atorvastatin 40 mg. **S**
- Keep refereeing full cards safely, without symptoms. In progress; target 2027-05-12. **S**
- Regression of left ventricular hypertrophy on a repeat echocardiogram. In progress; target 2027-05-26. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026), American College of Cardiology and American Heart Association (Circulation 2026;153(17):e1154-e1276)
- Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension (2015), American Heart Association and American College of Cardiology (Circulation 2015;132(22):e298-e302)
- CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026), Aether Forge

## Follow-up

- First hepatitis B vaccine dose today. Twenty-four-week review at the end of October with the second hepatitis B and zoster doses and the influenza vaccine. **S**
- Next scheduled visit 2026-10-27: twenty-four-week review: blood pressure control, symptoms at work, mood and worry, aspirin, and the plan ahead. **S**
